Bispecific antibody · Immune activation, directed at claudin 6 (CLDN6) and CD3 (CD3E) · developed by Xencor
XmAb541 is a bispecific antibody that binds claudin 6 (CLDN6) on tumor cells and CD3 on T-cells. By engaging both, it redirects cytotoxic T-lymphocytes to kill CLDN6-expressing tumor cells. It is being studied in ovarian cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07593092 | Phase 1 | Ovarian Cancer | Recruiting | XNCR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Ovarian Cancer
Updated Nov 1, 2026. Something wrong or missing? Report it on the XNCR page.
See XNCR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
XNCR catalysts and pipeline →